DTx Pharma, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

San Diego CA US

Primary Industry

Biotechnology

About

Based in California, US, and founded in 2017, DTx Pharma, Inc. operates as a biotechnology company that develops RNA-based therapeutics to treat genetic drivers of diseases. The company was founded by Arthur Suckow, John Grund, and Adam Pavlicek. In July 2023, Novartis acquired DTx Pharma, Inc. for USD 500 million, including an additional USD 500 million on achievement of pre-specified milestones. The company provides a FALCON platform (Fatty Acid Ligand Conjugated OligoNucleotide) that enables the delivery of RNA therapeutics for neuromuscular diseases. Following the acquisition, Novartis aims to advance the development of DTx Pharma, Inc.'s CMT1A therapeutic program and the FALCON platform.

Current Investors

Tech Coast Angels, Friedman Bioventures, ExSight Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.dtxpharma.com

Company Stage

Acquired

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.